Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

P. Cannon, Christopher; K. McGuire, Darren; E. Pratley, Richard; Dagogo‐Jack, Sam; P. Mancuso, James; Huyck, Susan; Charbonnel, B; Shih, Weichung; Gallo, Silvina; Masiukiewicz, Urszula; T. Golm, Gregory; Cosentino, Francesco; Lauring, Brett; G. Terra, Steven

doi:10.1016/j.ahj.2018.08.016

Public

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Published in American Heart Journal • Sep 5, 2018

Authors:

Christopher P. Cannon

Darren K. McGuire

Richard E. Pratley

Abstract

BACKGROUND: Ertugliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), approved in the United States and European Union to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objective to de...

Subject

Medicine

Internal medicine

Stroke (engine)

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!